- SVB Leerink initiated coverage on Karuna Therapeutics Inc (NASDAQ:KRTX) with an Outperform rating and a price target of $170.
- SVB notes that Karuna already has one positive schizophrenia study (EMERGENT-1) with KarXT. Thus, it only needs one of the two ongoing pivotal studies (EMERGENT-2 or EMERGENT-3) to file for psychosis in schizophrenia successfully.
- Related: JMP Views Positive Phase 3 Data Equivalent To ‘Schizophrenia Blockbuster’ For This Stock.
- The analysts also say that a second potential indication for KarXT in treatment-resistant schizophrenia as an adjunctive treatment could also be a significant opportunity, given that only clozapine is approved.
- Read Next: Mizuho Sees Compelling Risk/Reward For This Schizophrenia Stock Despite Recent Weakness.
- The analysts assume non-risk-adjusted peak sales of KarXT of $1.2 billion for schizophrenia, $500 million for the additional treatment-resistant schizophrenia indication, $1.7 billion for the additional negative/cognitive symptoms of schizophrenia indication, and $2.3 billion for the additional Alzheimer’s disease psychosis indication.
- Price Action: KRTX shares are up 1.95% at $131.38 during the market session on the last check Thursday.
QIAGEN Enhances Bioinformatics Workflows With New Secondary Analysis Solution For Oncology And Inherited Disease Applications
QIAGEN (NYSE:QGEN, Frankfurt Prime Standard: QIA)))) today announced the availability of QCI Secondary Analysis, a cloud-based software-as-a-services (SaaS) solution enabling high-throughput secondary analysis for
